Herceptin Price Drop Is ‘Pretty Promising,’ But May Not Be Replicable for All Biologics
The introduction of five Herceptin (trastuzumab) biosimilars contributed to a 21% decline in the cancer drug’s average sales price from the first quarter of 2019 to the second quarter of 2022, according to a study published this month in Health Affairs. Alice J. Chen, the study’s lead author, tells AIS Health that the adoption of Herceptin biosimilars and subsequent price decrease of the biologic is “a pretty promising case” at a time when biosimilars’ cost-saving potential is generating considerable interest.
However, Chen says the uptake of other drugs’ biosimilars has varied, leading to more modest price declines and questions about how much the health care industry will save as a flood of biosimilars becomes available in the U.S. in the coming years.
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
